Antipsychotic medications are sometimes used in nursing homes to manage behavioral symptoms in residents with dementia or other cognitive impairments. While these drugs may seem like a solution for agitation, aggression, or hallucinations, they come with serious risks and potential regulatory penalties if used inappropriately.
According to the Centers for Medicare & Medicaid Services (CMS), overuse of antipsychotics in nursing homes remains a critical issue. The federal government and advocacy organizations like Qsource are actively working to reduce unnecessary antipsychotic prescriptions and promote safer, more person-centered approaches.
Antipsychotic medications are not approved by the FDA to treat dementia-related behaviors, yet they are frequently prescribed off-label for this purpose. Unfortunately, this can lead to devastating health consequences for residents.
The FDA has issued a black box warning for all antipsychotics, cautioning that elderly patients with dementia-related psychosis are at an increased risk of death when taking these medications. The leading causes of death include:
A 2015 study published in JAMA Psychiatry found that the mortality risk is significantly higher in the first 180 days of antipsychotic use, making it especially dangerous when prescribed as a quick fix.
Antipsychotics do not cure dementia—they primarily work by suppressing brain activity to reduce agitation and aggression. This sedation often leads to:
Instead of improving behaviors, these medications often accelerate cognitive decline, making it harder for residents to interact with others and engage in meaningful activities.
Many antipsychotics cause dizziness, muscle weakness, and impaired coordination, which drastically increases the risk of falls. In nursing home residents, falls can lead to severe injuries, including:
A 2020 study in the Journal of the American Geriatrics Society found that nursing home residents on antipsychotics were 1.6 times more likely to experience falls and fractures.
Antipsychotic medications affect dopamine and serotonin receptors, which play a role in blood pressure regulation and cardiovascular health. This can lead to:
For residents with pre-existing heart conditions, antipsychotics can be life-threatening.
Long-term antipsychotic use is linked to significant metabolic issues, including:
Many residents on atypical antipsychotics (such as Olanzapine and Risperidone) experience rapid weight gain, making existing health conditions even harder to manage.
Sedation from antipsychotics can impair swallowing ability, leading to aspiration pneumonia—one of the most common causes of hospitalization and death in elderly residents. This is especially concerning for:
Studies show that elderly patients taking antipsychotics are twice as likely to develop aspiration pneumonia than those who are not.
Learn about Our Consulting Services
The CMS National Partnership to Improve Dementia Care has set clear goals to reduce unnecessary antipsychotic use in nursing homes. Facilities that fail to comply face significant penalties.
Families have successfully sued nursing homes for wrongful death and neglect linked to inappropriate antipsychotic prescribing. Without proper documentation and informed consent, facilities can face severe legal and financial consequences.
Organizations like Qsource provide critical support to help nursing homes:
Inappropriate antipsychotic use puts residents at risk and exposes nursing homes to regulatory penalties. While these medications may be necessary in some cases, they should never be used as a first-line treatment for dementia-related behaviors.
By prioritizing non-drug interventions, obtaining informed consent, and following CMS guidelines, facilities can improve resident safety, well-being, and regulatory compliance.